# DESCRIPTION

## FIELD OF THE INVENTION

- define field of invention

## BACKGROUND

- introduce therapeutic monoclonal antibodies
- describe post-translational modifications
- discuss importance of controlling product quality attributes
- summarize existing methods for assessing PTMs

## SUMMARY OF THE INVENTION

- introduce method for predicting in vivo PTM concentration
- describe equation for predicting PTM concentration
- discuss determining in vivo rate constant
- describe method for determining exposure to PTM
- introduce two-compartment pharmacokinetic model
- discuss predicting PTM concentration after multiple administrations
- summarize various embodiments of the method

## DETAILED DESCRIPTION OF THE INVENTION

- introduce patent application structure

### Abbreviations Used Herein

- define abbreviations

### Definitions

- define antibody
- describe antibody fragments
- define Fc fusion proteins
- define receptor Fc fusion proteins
- define human antibody
- define subject
- define treat, treating, or treatment

### General Description

- introduce therapeutic monoclonal antibodies
- describe post-translational modifications
- discuss importance of PTMs
- describe PTMs during production and storage
- discuss PTMs after administration
- introduce analysis of PTMs
- describe assessment of PTMs
- discuss prediction of PTMs
- introduce modeling of PTMs
- describe application of models
- discuss benefits of models

### Therefore:

- derive PTM equations
- solve equation constants
- describe PTM embodiments
- introduce predictive modeling
- describe computer system components
- detail system bus and memory
- describe input/output devices
- explain networked environment
- illustrate distributed computing environment
- describe software and database distribution

## EXAMPLE

- provide example disclosure

### Example 1

- introduce therapeutic monoclonal antibody MAB1
- describe PTM attributes of MAB1
- outline materials and methods
- detail preclinical sample information
- describe affinity purification of MAB1 from serum samples
- outline tryptic digestion and LC-MS/MS analysis
- calculate subject's exposure to quality attribute in single-dose PK study
- model subject's exposure to quality attribute in multiple-dose PK study
- describe calculation of subject's exposure to quality attribute in multiple-dose PK study
- provide equations for modeling subject's exposure to quality attribute
- derive equations for deamidation
- simplify equations for steady-state levels
- describe experimental methods for quantitation
- present results of PTM quantitation
- discuss deamidation rates and sites
- motivate use of first-order rate equation
- fit equation to experimental data
- introduce multiple-dose study
- describe deamidation of Asn Site 1
- describe deamidation of Asn Sites 2 and 3
- describe Met oxidation
- describe N-terminal pyroglutamate formation
- describe C-terminal lysine removal
- describe N-linked glycosylation
- model subject's exposure to MAB1 PQAs in single-dose study
- describe MAB1 serum concentration-time profile
- model subject's exposure to deamidation at Asn site 2
- model subject's exposure to deamidation at Asn site 3
- model subject's exposure to N-terminal pyroglutamate
- model subject's exposure to MAB1 PQAs in multiple-dose study
- model in vivo relative abundances of MAB1 PQAs in multiple-dose study
- describe example applications of the models
- describe predicting subject's exposure to PQAs
- describe evaluating impact of changes in initial levels of PQAs

## DISCUSSION

- motivate in vivo PQA quantitation
- discuss limitations of in vitro studies
- summarize in vivo PQA changes and modeling
- discuss scope of invention

